What is Wedbush’s Forecast for STOK FY2029 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their FY2029 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.41) per share for the year. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other analysts have also recently issued research reports about the company. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $24.00 price target on the stock. Finally, Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Price Performance

STOK stock opened at $8.96 on Thursday. The business has a fifty day moving average price of $12.05 and a 200 day moving average price of $13.11. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58. The stock has a market capitalization of $474.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.95.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at $29,000. Intech Investment Management LLC acquired a new position in Stoke Therapeutics in the third quarter valued at about $160,000. The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Stoke Therapeutics during the third quarter worth about $192,000. Finally, Profund Advisors LLC acquired a new stake in shares of Stoke Therapeutics during the second quarter worth about $201,000.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Barry Ticho sold 2,586 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $33,592.14. Following the sale, the insider now directly owns 44,746 shares in the company, valued at $581,250.54. This trade represents a 5.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. This represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.